킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American Thoracic Society (ATS) 2021

14 May - 19 May, 2021, United States

Antibody cocktail cuts hospitalization, death in COVID-19

2021-09-10

The REGN-COV2 monoclonal antibody cocktail comprising casirivimab and imdevimab significantly reduces the risk of hospitalization and all-cause death by 71 percent compared with placebo in nonhospitalized patients with COVID-19, according to a large phase III study presented at the ATS 2021 Meeting.
Budesonide-albuterol lowers exercise-induced bronchoconstriction in patients with asthma

2021-09-10

Treatment with a fixed-dose combination of budesonide and albuterol (BDA) in a single pressurized metered-dose inhaler (pMDI), also known as PT027, significantly prevents exercise-induced bronchoconstriction (EIB) in adolescents and adults with asthma, according to the TYREE* study presented at ATS 2021.
COPD tied to excess death risk, even in younger adults

2021-09-10

Younger adults with chronic obstructive pulmonary disease (COPD) have excess risk of morbidity and mortality, contrary to common belief that the disease is mild at younger age, according to a longitudinal, population-base cohort study presented at the ATS 2021 Meeting.
Dupilumab may reduce exacerbations in paediatric uncontrolled asthma

2021-09-10

Children with uncontrolled moderate-to-severe asthma may benefit from treatment with dupilumab which reduced exacerbations and improved lung function, according to results of the phase III VOYAGE study presented at ATS 2021.
Inhaled treprostinil tied to favourable outcomes in PH-ILD

2021-09-10

In post hoc analyses of the phase III INCREASE trial presented at ATS 2021, patients on inhaled treprostinil (iTre) for pulmonary hypertension due to parenchymal lung disease (PH-ILD) were less inclined to have multiple clinical worsening events and more likely to experience clinical improvement vs those on placebo.
Long-term study findings reflect potential of sotatercept for PAH

2021-09-10

The efficacy and safety of the novel, first-in-class, selective fusion protein sotatercept were sustained or enhanced for up to 48 weeks when added to standard of care (SOC) for the treatment of pulmonary arterial hypertension (PAH), according to interim findings of the ongoing open-label extension (OLE) period of the phase II PULSAR trial presented at ATS 2021.
NAVIGATOR: Smooth sailing across the board for tezepelumab in severe asthma

2021-09-10

The specific TSLP* inhibitor tezepelumab significantly reduces exacerbation rates across a broad spectrum of patients with severe, uncontrolled asthma, regardless of the status of key inflammatory biomarkers, according to the NAVIGATOR study presented at ATS 2021.
Sleep apnoea may increase, and PAP use decrease, COVID-19 risk

2021-09-10

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.
Tocilizumab administration for severe COVID-19: Timing matters

2021-09-10

Early administration (ie, pre-intubation/noninvasive ventilation) of the interleukin-6 receptor blocker tocilizumab in patients with severe COVID-19 led to more favourable outcomes compared with late administration (ie, post-intubation/noninvasive ventilation), according to data presented at ATS 2021.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 소현정 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (09:00~18:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2022 KIMS Co., Ltd All Rights Reserved

KIMS APP

KIMS 페이스북

KIMS 트위터